Abstract
Molecules that inhibit histone deacetylases (HDACs) activity have shown a great promise as anticancer agents since they interfere with cell proliferation and angiogenesis, induce cell differentiation and promote apoptosis. A number of HDACIs (for example: SAHA) have been approved by FDA for the treatment of cancer in different stages of clinical trials. HDAC inhibition proves to be a worthy strategy for cancer therapy. Thus, the distribution and metabolism of HDACIs in vivo are of significant clinical value for diagnosis and assessment of therapeutic efficacy. Molecular imaging is one of the primary tools used to noninvasively evaluate biological processes at the cellular and molecular level in living subjects. Various imaging modalities, including optical bioluminescence/ fluorescence, PET, SPECT, MRI, CT and US are all successfully used to assess the anatomic or functional dissemination of tissues and specific molecular targets, such as imaging molecular interactions, tumor vitality, apoptosis, angiogenesis and response to cancer treatment in the body. The utility of molecular imaging for monitoring HDACIs provides a perfect strategy for deeper understanding about cancer. In this article, the recent progresses of molecular imaging for assessing HDACIs are reviewed. In addition, how imaging can be used, at least experimentally, to assess specific molecular targets is also discussed.
Keywords: Histone deacetylase, Histone deacetylase inhibitors, Cancer therapy, Molecular imaging, PET, Optical imaging, TOMO- GRAPHY, Myeloma, Colon Carcinoma, Brain Cancer
Anti-Cancer Agents in Medicinal Chemistry
Title: Molecular Probing and Imaging of Histone Deacetylase Inhibitors in Cancer Treatment
Volume: 12 Issue: 3
Author(s): Huang Jiaguo, Liu Zhiguo and Zeng Wenbin
Affiliation:
Keywords: Histone deacetylase, Histone deacetylase inhibitors, Cancer therapy, Molecular imaging, PET, Optical imaging, TOMO- GRAPHY, Myeloma, Colon Carcinoma, Brain Cancer
Abstract: Molecules that inhibit histone deacetylases (HDACs) activity have shown a great promise as anticancer agents since they interfere with cell proliferation and angiogenesis, induce cell differentiation and promote apoptosis. A number of HDACIs (for example: SAHA) have been approved by FDA for the treatment of cancer in different stages of clinical trials. HDAC inhibition proves to be a worthy strategy for cancer therapy. Thus, the distribution and metabolism of HDACIs in vivo are of significant clinical value for diagnosis and assessment of therapeutic efficacy. Molecular imaging is one of the primary tools used to noninvasively evaluate biological processes at the cellular and molecular level in living subjects. Various imaging modalities, including optical bioluminescence/ fluorescence, PET, SPECT, MRI, CT and US are all successfully used to assess the anatomic or functional dissemination of tissues and specific molecular targets, such as imaging molecular interactions, tumor vitality, apoptosis, angiogenesis and response to cancer treatment in the body. The utility of molecular imaging for monitoring HDACIs provides a perfect strategy for deeper understanding about cancer. In this article, the recent progresses of molecular imaging for assessing HDACIs are reviewed. In addition, how imaging can be used, at least experimentally, to assess specific molecular targets is also discussed.
Export Options
About this article
Cite this article as:
Jiaguo Huang, Zhiguo Liu and Wenbin Zeng, Molecular Probing and Imaging of Histone Deacetylase Inhibitors in Cancer Treatment, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (3) . https://dx.doi.org/10.2174/187152012800228779
DOI https://dx.doi.org/10.2174/187152012800228779 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging Roles of microRNAs in the Molecular Responses to Hypoxia
Current Pharmaceutical Design State of Research Tracks and Property Protection of Photodynamic Sensitizers and Delivery Methodologies
Recent Patents on Chemical Engineering Mitochondria-Targeting Anticancer Metal Complexes
Current Medicinal Chemistry CYP4 Enzymes As Potential Drug Targets: Focus on Enzyme Multiplicity, Inducers and Inhibitors, and Therapeutic Modulation of 20- Hydroxyeicosatetraenoic Acid (20-HETE) Synthase and Fatty Acid ω- Hydroxylase Activities
Current Topics in Medicinal Chemistry Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research Radiolabeled RGD Peptides as Integrin alpha(v)beta3–targeted PET Tracers
Current Medicinal Chemistry Post-Wortmannin Era: Novel Phosphoinositide 3-Kinase Inhibitors with Potential Therapeutic Applications
Current Enzyme Inhibition Pharmacokinetics and Acute Toxicity of a Histone Deacetylase Inhibitor, Scriptaid, and its Neuroprotective Effects in Mice After Intracranial Hemorrhage
CNS & Neurological Disorders - Drug Targets Intra-arterial Temozolomide, Osmotic Blood-brain Barrier Disruption and Radiotherapy in a Rat F98-Glioma Model
Clinical Cancer Drugs Role of Natural Killer Cell Activity in the Pathogenesis of Endometriosis
Current Medicinal Chemistry Microbicidal Tissue Paper Using Green Synthesized Silver Nanoparticles
Current Nanoscience Dietary Phytochemicals in Chemoprevention of Cancer: An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cannabinoids as Neuroprotective Agents in Traumatic Brain Injury
Current Pharmaceutical Design Antineoplastic Activity, Structural Modification, Synthesis and Structure-activity Relationship of Dammarane-type Ginsenosides: An Overview
Current Organic Chemistry Somatostatin: A Hormone for the Heart?
Current Vascular Pharmacology Specific Cytostatic and Cytotoxic Effect of Dihydrochelerythrine in Glioblastoma Cells: Role of NF-κB/β-catenin and STAT3/IL-6 Pathways
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs in Prostate Cancer Following Radiotherapy: Towards Predicting Response to Radiation Treatment
Current Medicinal Chemistry Protein Kinase C Isozymes as Potential Targets for Anticancer Therapy
Current Cancer Drug Targets Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions
Current Molecular Medicine Isolation, Characterization and Preliminary Cytotoxic and Antifungal Evaluations of Novel Lancifoliate Isolated from Methanol Extract of <i>Conocarpus lancifolius</i>
Anti-Cancer Agents in Medicinal Chemistry